ATP6AP1

V-type proton ATPase subunit S1 · Q15904 · ATP6AP1 on Sugi Atlas →

508 patent compounds predicted against ATP6AP1, 442 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Bafilomycin A1 (SCHEMBL13775181)	1.00	1/20
Bafilomycin A1 (SCHEMBL13778448)	1.00	1/20
Bafilomycin A1 (SCHEMBL13990314)	1.00	1/20
SCHEMBL14387194	1.00	1/20
Bafilomycin A1 (SCHEMBL20768056)	1.00	1/20
Bafilomycin A1 (SCHEMBL20768057)	1.00	1/20
Bafilomycin A1 (SCHEMBL27111880)	1.00	1/20
Bafilomycin A1 (SCHEMBL29355819)	1.00	1/20
Bafilomycin A1 (SCHEMBL29360579)	1.00	1/20
Bafilomycin A1 (SCHEMBL29396438)	1.00	1/20
SCHEMBL22590602	0.88	1/20
SCHEMBL23550703	0.88	1/20
SCHEMBL2402916	0.87	1/20
SCHEMBL2402919	0.87	1/20
SCHEMBL2402921	0.87	1/20
SCHEMBL29798849	0.87	1/20
SCHEMBL27111622	0.85	1/20
SCHEMBL27111865	0.85	1/20
SCHEMBL29745728	0.85	1/20
SCHEMBL17754426	0.84	1/20

Clinical trials — most relevant to ATP6AP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer	PHASE3	COMPLETED
Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation	PHASE2/PHASE3	UNKNOWN
Copper Histidine Therapy for Menkes Diseases	PHASE1/PHASE2	COMPLETED
Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood	PHASE2	COMPLETED
Natural History Study of ATP1A3-related Disease	nan	UNKNOWN
Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease	nan	RECRUITING
Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients	nan	ACTIVE_NOT_RECRUITING
CHOPXE - Analysis of Choriocapillaris Flow Deficits in Patients With Pseudoxanthoma Elasticum	nan	RECRUITING
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial	nan	ACTIVE_NOT_RECRUITING
Natural History of GACI With or Without ARHR2 or PXE	nan	UNKNOWN
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency	nan	COMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias	nan	COMPLETED
The Energetic Origin of Neurodegeneration in MS	nan	COMPLETED
Coproporphyrine Isomers and Methotrexate Elimination	nan	COMPLETED
Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions	nan	WITHDRAWN
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer	nan	UNKNOWN
Heart and Skeletal Muscle Problems in Neuroacanthocytosis	nan	COMPLETED
CIQTP Prolongation : Role and Mechanism in Sudden Cardiac Death	nan	COMPLETED
Pediatric Cardiomyopathy Mutation Analysis	nan	RECRUITING
Genetic Analysis of Patients With Pseudoxanthoma Elasticum	nan	COMPLETED
Diagnosis of Primary Ciliary Dyskinesia	nan	COMPLETED
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve	nan	UNKNOWN
Genetic Analysis of Hereditary Disorders of Hearing and Balance	nan	COMPLETED
Core Stability Exercises and Hereditary Ataxia	nan	COMPLETED
Influence of Diabetic Neuropathy on Activation of Brown Adipose Tissue	nan	UNKNOWN
Genetic Basis of Non Syndromic Congenital Diaphragmatic Hernia	nan	COMPLETED
Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome	nan	COMPLETED
Exome Analysis in Hearing Impaired Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ATP6AP1 binder may also engage these)

Protein	Name	Similarity
Q9R1Q9	—	0.997	Q9R1Q9 →
P40682	—	0.994	P40682 →
O54715	—	0.992	O54715 →
Q9JHJ3	—	0.984	Q9JHJ3 →
Q8WWB7	—	0.983	Q8WWB7 →
Q60696	—	0.981	Q60696 →
Q68FV6	—	0.980	Q68FV6 →
Q5R5V2	—	0.978	Q5R5V2 →
Q9H0X4	—	0.977	Q9H0X4 →
Q2HJE5	—	0.976	Q2HJE5 →
Q9HCN3	—	0.975	Q9HCN3 →
P0C8N6	—	0.975	P0C8N6 →
O14525	—	0.974	O14525 →
Q5RJL6	—	0.974	Q5RJL6 →
Q9C0H2	—	0.974	Q9C0H2 →
H2N4I1	—	0.974	H2N4I1 →
Q96F46	—	0.973	Q96F46 →
Q16586	—	0.973	Q16586 →
Q8CEF9	—	0.973	Q8CEF9 →
A4IGL3	—	0.973	A4IGL3 →
Q8BZ64	—	0.973	Q8BZ64 →
Q400G9	—	0.973	Q400G9 →
A4FV27	—	0.973	A4FV27 →
Q9D387	—	0.973	Q9D387 →
Q8IUH8	—	0.972	Q8IUH8 →
F1NNL1	—	0.972	F1NNL1 →
P59240	—	0.972	P59240 →
Q5RBU0	—	0.972	Q5RBU0 →
Q9UJQ1	—	0.972	Q9UJQ1 →
A8WFR0	—	0.972	A8WFR0 →